Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives - PubMed (original) (raw)
Review
Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives
Newman Yeilding et al. Ann N Y Acad Sci. 2011 Mar.
Abstract
The development of ustekinumab as a first-in-class anti-interleukin (IL) 12/23p40 therapeutic agent for psoriasis represents an important example of modern and rational drug design and development. Psoriasis is a chronic, systemic, immune-mediated skin disorder with considerable clinical, psychosocial, and economic burden. Ustekinumab is a human monoclonal antibody (mAb) that binds the p40 subunit common to IL-12 and IL-23, key cytokines in psoriasis pathogenesis. The therapeutic mAb was developed using human gamma-1 immunoglobulin (IgG)-expressing transgenic mice, which created a molecule with endogenous IgG(1) biologic properties and low immunogenicity. Ustekinumab was well tolerated in clinical studies and yielded rapid, significant, and sustained efficacy plus improved quality of life/work performance and reduced depression/anxiety. Its pharmacologic properties afford the most convenient dosing regimen among approved biologics, representing a significant advancement in the treatment of moderate to severe psoriasis. Ustekinumab also holds promise for other immune-mediated disorders with significant unmet need.
© 2011 New York Academy of Sciences.
Similar articles
- Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update.
Yeilding N, Szapary P, Brodmerkel C, Benson J, Plotnick M, Zhou H, Goyal K, Schenkel B, Giles-Komar J, Mascelli MA, Guzzo C. Yeilding N, et al. Ann N Y Acad Sci. 2012 Aug;1263:1-12. doi: 10.1111/j.1749-6632.2012.06670.x. Epub 2012 Jul 23. Ann N Y Acad Sci. 2012. PMID: 22823582 Review. - Anti-p40 antibodies ustekinumab and briakinumab: blockade of interleukin-12 and interleukin-23 in the treatment of psoriasis.
Gandhi M, Alwawi E, Gordon KB. Gandhi M, et al. Semin Cutan Med Surg. 2010 Mar;29(1):48-52. doi: 10.1016/j.sder.2010.02.001. Semin Cutan Med Surg. 2010. PMID: 20430307 Review. - Does p40-targeted therapy represent a significant evolution in the management of plaque psoriasis?
Griffiths CE, Girolomoni G. Griffiths CE, et al. J Eur Acad Dermatol Venereol. 2012 Aug;26 Suppl 5:2-8. doi: 10.1111/j.1468-3083.2012.04604.x. J Eur Acad Dermatol Venereol. 2012. PMID: 22758911 Review. - Monoclonal antibodies inhibiting IL-12, -23, and -17 for the treatment of psoriasis.
Jeon C, Sekhon S, Yan D, Afifi L, Nakamura M, Bhutani T. Jeon C, et al. Hum Vaccin Immunother. 2017 Oct 3;13(10):2247-2259. doi: 10.1080/21645515.2017.1356498. Hum Vaccin Immunother. 2017. PMID: 28825875 Free PMC article. Review. - Novel biologic therapies in development targeting IL-12/IL-23.
van de Kerkhof PC. van de Kerkhof PC. J Eur Acad Dermatol Venereol. 2010 Oct;24 Suppl 6:5-9. doi: 10.1111/j.1468-3083.2010.03830.x. J Eur Acad Dermatol Venereol. 2010. PMID: 20831703
Cited by
- Signaling pathways and targeted therapies for psoriasis.
Guo J, Zhang H, Lin W, Lu L, Su J, Chen X. Guo J, et al. Signal Transduct Target Ther. 2023 Nov 27;8(1):437. doi: 10.1038/s41392-023-01655-6. Signal Transduct Target Ther. 2023. PMID: 38008779 Free PMC article. Review. - Body Mass Index Influence for the Personalization of the Monoclonal Antibodies Therapy for Psoriasis.
Anghel F, Nitusca D, Cristodor P. Anghel F, et al. Life (Basel). 2021 Nov 29;11(12):1316. doi: 10.3390/life11121316. Life (Basel). 2021. PMID: 34947847 Free PMC article. Review. - Immunogenicity to biological drugs in psoriasis and psoriatic arthritis.
Valenzuela F, Flores R. Valenzuela F, et al. Clinics (Sao Paulo). 2021 Oct 1;76:e3015. doi: 10.6061/clinics/2021/e3015. eCollection 2021. Clinics (Sao Paulo). 2021. PMID: 34614113 Free PMC article. - Weighted gene coexpression network and experimental analyses identify lncRNA SPRR2C as a regulator of the IL-22-stimulated HaCaT cell phenotype through the miR-330/STAT1/S100A7 axis.
Luo M, Huang P, Pan Y, Zhu Z, Zhou R, Yang Z, Wang C. Luo M, et al. Cell Death Dis. 2021 Jan 15;12(1):86. doi: 10.1038/s41419-020-03305-z. Cell Death Dis. 2021. PMID: 33452236 Free PMC article. - Human αβ and γδ T Cells in Skin Immunity and Disease.
Cruz MS, Diamond A, Russell A, Jameson JM. Cruz MS, et al. Front Immunol. 2018 Jun 6;9:1304. doi: 10.3389/fimmu.2018.01304. eCollection 2018. Front Immunol. 2018. PMID: 29928283 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous